Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • GSK ovarian cancer...

    GSK ovarian cancer drug Zejula gets USFDA nod for wider use

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-10-24T10:00:07+05:30  |  Updated On 17 Aug 2021 11:48 AM IST

    Zejula was the lead compound of U.S. cancer specialist Tesaro, which GSK acquired for $5.1 billion last year. Zejula brought in sales of 57 million pounds ($73.59 million) in the second quarter.


    New Delhi: GlaxoSmithKline said U.S. regulators had approved its ovarian cancer treatment Zejula for wider use in some advanced cancers, in a boost to the British drugmaker's oncology portfolio as it competes with rival AstraZeneca.


    The U.S. Food and Drug Administration approval is for the drug's use in advanced ovarian, fallopian tube, or primary peritoneal cancer patients who have undergone at least three prior chemotherapy regimens and whose disease has come back.


    Zejula is currently approved as maintenance therapy for adults with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer and whose tumours have completely or partially responded to platinum-based chemotherapy treatments.


    Zejula was the lead compound of U.S. cancer specialist Tesaro, which GSK acquired for $5.1 billion last year. Zejula brought in sales of 57 million pounds ($73.59 million) in the second quarter.


    The FDA nod was based on a trial that showed the benefit of using Zejula to treat tumours whether or not the women had mutated BRCA genes which hamper DNA repairs, but also in women with a wider range of genetic mutations, grouped together under the term homologous recombination deficiency (HRD).


    Currently, AstraZeneca and Merck & Co's Lynparza is seen as a leading PARP inhibitor, a class of medicines to which Zejula belongs, with analysts forecasting average sales of $3.1 billion for 2023. Zejula, approved in 2017 by the FDA, is expected to achieve about 870 million pounds ($1.12 billion) in revenue that year.


    Read Also: AstraZeneca scores win in a race to treat ovarian cancer


    Both Lynparza and Zejula have shown promise in ovarian cancer patients with BRCA and HRD mutations. With the approval, GSK has now become the first to be allowed to market its treatment in the HRD setting.


    The approval underscores the potential of PARP inhibitors for use across a wider gene pool and beyond ovarian cancer.


    Other approved PARP inhibitors include Pfizer's Talzenna and Clovis Oncology's Rubraca. Abbvie is testing an experimental compound called Veliparib.


    The approval is also a boost to GSK's comeback into cancer therapies. The drugmaker had sold its approved oncology drugs to Novartis in 2014.


    Read Also: GSK drug Zejula helps ovarian cancer patients live longer in a late-stage study

    AstraZenecaBRCA genescancerchemotherapyfallopian tubeGlaxoSmithKlineGSKhomologous recombination deficiencyHRDNovartisovarian cancer drugPfizerRubracatalzennaTesarotumourUS Food and Drug AdministratioUSFDAUSFDA nodveliparibZejula
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok